About Us
Company Overview
Executive Team
Board of Directors
Contact
Science & Pipeline
Pipeline
R&D Platform
Publications
Patients
Partners
Business Development
Media
Press Release
Careers
Corporate Culture
Job Opportunities
Investors
中文
中文
About Us
Company Overview
Executive Team
Board of Directors
Scientific Advisory Board
Contact
Science & Pipeline
Pipeline
R&D Platform
Publications
Patients
Partners
Business Development
Media
Press Release
Media Report
Careers
Corporate Culture
Job Opportunities
Investors
Transform Deadly Cancer into a Chronic and Eventually Curable Disease
Pipeline
AN9025
AN8025
AN4005
EAP
我们的核心产品AN2025 (buparisib)将有可能成为全球首个获批，用于治疗后复发性或转移性HNSCC的二线治疗药物，这仍是一个巨大的未满足临床需求领域。
产品代码/名称
适应症
药物发现
IND申报
1a期
1b期
2期
3期
AN9025
oral pan-KRAS inhibitor
AN8025
T cell/APC modulator
AN4005
oral PD-L1 inhibitor
